Cardiol Res

Cardiology Research, ISSN 1923-2829 print, 1923-2837 online, Open Access

Article copyright, the authors; Journal compilation copyright, Cardiol Res and Elmer Press Inc

Journal website https://www.cardiologyres.org

Original Article

Volume 9, Number 1, February 2018, pages 11-16

The Severity of Coronary Arterial Stenosis in Patients With Acute ST-Elevated Myocardial Infarction: A Thrombolytic Therapy Study

**Table 1.** Basal Characteristic Features and Laboratory Values of the Patients
Variables	All patients (n = 267)	IRA ≥ 50% (n = 236)	IRA < 50% (n = 31)	P
CAD: coronary artery disease; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; LVEF: left ventricular ejection fraction; MI-CAG: myocardial infarction-coronary angiography.
Age	55.7 ± 10.8	56.1 ± 10.4	51.4 ± 12.9	0.617
Median MI-CAG time (days) (max. - min.)	8 (1 - 17)	8 (1 - 17)	5 (1 - 14)	0.571
Pain onset-admission
< 1 h, % (n)	44 (119)	44 (104)	48.4 (15)	0.869
1 - 3 h, % (n)	33 (88)	33 (79)	29 (9)
> 3 h, % (n)	22 (60)	22 (53)	22 (7)
LVEF, %	44.8 ± 9	44.4 ± 9	47.8 ± 9	0.08
Hypertension, % (n)	40.1 (107)	41.6 (99)	27.6 (8)	0.14
Hyperlipidemia	25.8 (69)	25.2 (60)	31 (9)
Diabetes mellitus	27.7 (74)	27.3 (65)	31 (9)	0.614
Family history	37.1 (99)	36.6 (87)	41.4 (29)	0.632
Smoking	76.8 (205)	77.3 (184)	72.4 (21)	0.543
History of CAD	25.8 (69)	25.2 (60)	31 (9)	0.412
Obesity	25.8 (69)	23.5 (56)	44.8 (13)	0.013
Creatine (mg/dL)	1.02 ± 0.3	1.01 ± 0.05	1.02 ± 0.02	0.85
Hemoglobin (mg/dL)	14.4 ± 1.7	14.4 ± 2	14 ± 1.6	0.86
Total cholesterol (mg/dL)	193 ± 45.2	181 ± 36	195 ± 46	0.13
LDL-C (mg/dL)	119.3 ± 39.6	106 ± 28	120 ± 40.8	0.06
HDL-C (mg/dL)	40.7 ± 1.2	43 ± 11	40.5 ± 11	0.211
Triglycerides (mg/dL)	172 ± 112	149 ± 71.6	176 ± 117	0.226

Table 1. Basal Characteristic Features and Laboratory Values of the Patients

Variables

All patients (n = 267)

IRA ≥ 50% (n = 236)

IRA < 50% (n = 31)

CAD: coronary artery disease; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; LVEF: left ventricular ejection fraction; MI-CAG: myocardial infarction-coronary angiography.

Age

55.7 ± 10.8

56.1 ± 10.4

51.4 ± 12.9

0.617

Median MI-CAG time (days) (max. - min.)

8 (1 - 17)

5 (1 - 14)

0.571

Pain onset-admission

< 1 h, % (n)

44 (119)

44 (104)

48.4 (15)

0.869

1 - 3 h, % (n)

33 (88)

33 (79)

29 (9)

> 3 h, % (n)

22 (60)

22 (53)

22 (7)

LVEF, %

44.8 ± 9

44.4 ± 9

47.8 ± 9

0.08

Hypertension, % (n)

40.1 (107)

41.6 (99)

27.6 (8)

0.14

Hyperlipidemia

25.8 (69)

25.2 (60)

31 (9)

Diabetes mellitus

27.7 (74)

27.3 (65)

31 (9)

0.614

Family history

37.1 (99)

36.6 (87)

41.4 (29)

0.632

Smoking

76.8 (205)

77.3 (184)

72.4 (21)

0.543

History of CAD

25.8 (69)

25.2 (60)

31 (9)

0.412

Obesity

25.8 (69)

23.5 (56)

44.8 (13)

0.013

Creatine (mg/dL)

1.02 ± 0.3

1.01 ± 0.05

1.02 ± 0.02

0.85

Hemoglobin (mg/dL)

14.4 ± 1.7

14.4 ± 2

14 ± 1.6

0.86

Total cholesterol (mg/dL)

193 ± 45.2

181 ± 36

195 ± 46

0.13

LDL-C (mg/dL)

119.3 ± 39.6

106 ± 28

120 ± 40.8

0.06

HDL-C (mg/dL)

40.7 ± 1.2

43 ± 11

40.5 ± 11

0.211

Triglycerides (mg/dL)

172 ± 112

149 ± 71.6

176 ± 117

0.226

**Table 2.** Angiographic Data After Successful Thrombolytic Therapy
Variable	IRA ≥ 50%	IRA < 50%	P
Left anterior descending coronary artery, % (n)	45 (105)	48 (15)	0.671
Left circumflex coronary artery, % (n)	10 (25)	10 (3)
Right coronary artery, % (n)	39 (91)	35 (11)
Other coronary vessel, % (n)	6 (15)	6 (2)
Diameter stenosis (%)	36 ± 9	77 ± 13	< 0.001

Table 2. Angiographic Data After Successful Thrombolytic Therapy

Variable

IRA ≥ 50%

IRA < 50%

Left anterior descending coronary artery, % (n)

45 (105)

48 (15)

0.671

Left circumflex coronary artery, % (n)

10 (25)

10 (3)

Right coronary artery, % (n)

39 (91)

35 (11)

Other coronary vessel, % (n)

6 (15)

6 (2)

Diameter stenosis (%)

36 ± 9

77 ± 13

< 0.001

**Table 3.** Medical Treatment in Admission and During Hospitalization
Drug	All patients	IRA ≥ 50%	IRA < 50%	P
ACEI: angiotensin converting enzyme inhibitor; ARB: angiotensin receptor blocker; UFH: unfractioned heparin; LMWH: low molecular weight heparin; NS: non-significant.
Aspirin, %	100	100	100	NS
Clopidogrel, %	100	100	100	NS
UFH or LMWH, %	100	100	100	NS
Statins, %	97	97	100	NS
Beta blocker, %	94	94	90	NS
ACEI/ARB, %	92	93	87	NS
Nitrate, %	51	52	45	NS
Aspirin + clopidogrel + UFH or LWMH, %	100	100	100	NS

Table 3. Medical Treatment in Admission and During Hospitalization

Drug

All patients

IRA ≥ 50%

IRA < 50%

ACEI: angiotensin converting enzyme inhibitor; ARB: angiotensin receptor blocker; UFH: unfractioned heparin; LMWH: low molecular weight heparin; NS: non-significant.

Aspirin, %

100

Clopidogrel, %

100

UFH or LMWH, %

100

Statins, %

100

Beta blocker, %

ACEI/ARB, %

Nitrate, %

Aspirin + clopidogrel + UFH or LWMH, %

100